MDT-AP-0002
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 20.759999999999998
- os_event
- true
- age_years
- 3.65
- sex
- F
- new_clusters
- C1
- umap1_2d
- 4.397140161
- umap2_2d
- -0.462933545
- umap1_3d
- -0.270135257
- umap2_3d
- -3.624076671
- umap3_3d
- 0.200904776
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.430
- G2M_CHECKPOINT+0.370
- MYC_TARGETS_V2+0.370
- MYC_TARGETS_V1+0.340
- OXIDATIVE_PHOSPHORYLATION+0.280
- DNA_REPAIR+0.170
- MITOTIC_SPINDLE+0.170
- SPERMATOGENESIS+0.170
- WNT_BETA_CATENIN_SIGNALING+0.160
- MTORC1_SIGNALING+0.150
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.440
- ALLOGRAFT_REJECTION-0.320
- INTERFERON_ALPHA_RESPONSE-0.300
- IL6_JAK_STAT3_SIGNALING-0.280
- INFLAMMATORY_RESPONSE-0.280
- TNFA_SIGNALING_VIA_NFKB-0.280
- P53_PATHWAY-0.270
- HYPOXIA-0.260
- COMPLEMENT-0.250
- PANCREAS_BETA_CELLS-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2497 | Med | Medulloblastoma | 0.907 |
| 2 | MDT-AP-0164 | Med | Medulloblastoma | 0.906 |
| 3 | BS_V72H4RQS | medulloblastoma | — | 0.896 |
| 4 | TCGA-55-7570-01A-11R-2039-07 | — | cohortA3 | 0.896 |
| 5 | TCGA-C8-A1HN-01A-11R-A137-07 | — | B | 0.882 |
| 6 | BS_WVW3W6ZB | ATRT | — | 0.882 |
| 7 | BS_KVNGNETA | medulloblastoma | — | 0.879 |
| 8 | BS_TZVFR600 | Med | Medulloblastoma | 0.878 |
| 9 | SRR8518239 | — | E | 0.873 |
| 10 | TCGA-A1-A0SO-01A-22R-A084-07 | — | E | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.430 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.370 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.130 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.080 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.060 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.020 | Remibrutinib | — uncovered |